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ABSTRACT 
Objective: The antihyperglycaemic potentiality of Terminalia chebula leaves has not yet been investigated thoroughly compared to its fruit counterpart. 
Therefore, the purpose of this study was to assess the hypoglycaemic potentiality of Terminalia chebula Retz leaves both in vitro and in vivo. 
Methods: Fresh leaves of T. chebula were collected, authenticated and grounded to a fine powder. The powdered material was extracted in 
methanol. The hypoglycaemic potentiality of the extract was accessed in vitro using enzyme alpha-amylase and alpha-glucosidase. The 
antihyperglycaemic activity of the methanol extract active fraction was accessed in vitro and in vivo. The active fraction thus obtained was partially 
characterized using Fourier transform infrared spectroscopy (FTIR) and High-performance liquid chromatography (HPLC) analysis. 
Results: The crude leave methanol extract of Terminalia chebula demonstrated 100% α glucosidase inhibition with IC50–0.956±0.342 mg/ml 
compared to standard drug acarbose. Oral administration of the active fraction to diabetic rats loaded with maltose significantly (P<0.05) retarded 
the postprandial spike of blood glucose level compared to standard drug acarbose. Partial characterization of the fraction reveals the presence of 
hydrosoluble tannin gallic acid. 
Conclusion: The study provides an in vitro and in vivo rationale evidence of Terminalia chebula leaves to retard postprandial hyperglycemia. 
Keywords: Terminalia chebula, Postprandial hyperglycemia (PPHG), α amylase, α glucosidase, Active fraction (f5) 




Diabetes mellitus is a metabolic disorder characterized by high blood 
glucose level. Diabetes mellitus is caused due to relative or absolute 
deficiency of insulin or resistance to the action of insulin at the cellular 
level [1]. The abnormalities in metabolism of carbohydrate protein and 
fat are due to a deficient action of insulin on target tissues resulting from 
insensitivity or lack of insulin [2]. In developing countries, diabetes 
mellitus type 2 represents near about 90% of total people with diabetes. 
The percentage is much higher in developing countries [3]. One of the 
prominent and early symptoms of diabetes mellitus type 2 is 
postprandial hyperglycemia (PPHG). Postprandial hyperglycemia has 
been identified as an independent risk factor for developing 
cardiovascular disease in patients with or without diagnosed diabetes. 
Studies have shown that PPHG, instead of Fasting glucose, is a significant 
predictor of subsequent myocardial infarction and death in patients with 
newly diagnosed diabetes mellitus type 2 [4]. Drug with mild α amylase 
inhibition is considered as preferable for treatment of postprandial 
hyperglycaemia since the side effects related to very high inhibition of 
pancreatic α-amylase such as flatulence, abdominal distension, and 
diarrhoea etc caused by intake of drug acarbose, results in abnormal 
fermentation of undigested carbohydrate by of colon bacteria mark 
limitation in its use [5]. Therefore, α-glucosidase inhibitors are 
considered as better therapeutic to control the PPHG spike in diabetes 
mellitus type 2. Terminalia is a genus of large trees of the flowering plant, 
family Combretaceae, comprising around 100 species distributed in 
tropical regions of the world. Being a native plant of South East Asia, the 
dried ripe fruit of Terminalia chebula has traditionally been used to treat 
various aliments including diabetes [6-9]. Though several studies were 
conducted earlier upon the fruit part of T. chebula, the literature survey 
reveals that there is no previous report on the hypoglycaemic evaluation 
of the leaf part of the plant T. chebula, both in vitro and in vivo. Hence, in 
the current study, the leave methanol extract of the plant was used to 
access its hypoglycaemic potentiality in vitro and in vivo. 
MATERIALS AND METHODS 
Chemicals and reagents 
Alpha-glucosidase (EC 3.2.1.20) porcine pancreatic alpha-amylase 
enzyme (3.2.1.1) and alloxan monohydrate were procured from 
Sigma Co. USA. Standard drug acarbose was purchased from a 
nearby pharmaceutical shop of Guwahati. For estimating the blood 
glucose level, Glucometer Select One–touch was used. All solvent 
used in this study were of analytical grade. 
Collection of plant material 
Fresh leaves of Terminalia chebula Retz were collected from nearby 
areas of Gauhati University. The plant material collected was 
authenticated in the Department of Botany, Gauhati University, 
Guwahati with reference No. Herb/Bot/GU/2015/123 Terminalia 
chebula Retz family-Combretaceae (Acc. No.18084). Voucher 
specimens of the collected plant were deposited at Department of 
Botany, Gauhati University. 
Preparation of plant extract 
Collected leaves were shade dried, grounded to the fine powder and 
extracted subsequently in methanol, using a Soxhlet apparatus. The 
crude extract was concentrated using a rotary evaporator (BUCHI R II). 
The semisolid extract obtained was then stored at 4 °C until the assay. 
In vitro Alpha amylase inhibition assay of T. chebula extract 
α-amylase inhibition was determined using the modified version of 
the method according to Bernfield [10]. Briefly, 100 µl of test extract 
was allowed to react with 200 µl of the porcine pancreatic alpha-
amylase enzyme (Sigma Aldrich-3176) of 0.5unit/ml and 100 µl of 2 
mmol of sodium phosphate buffer (pH 6.9). After 20 min of 
incubation at 37 °C, 100 µl of 1% potato starch solution was then 
added. The same was performed for the blank, where 200 µl of an 
enzyme was replaced by the buffer. After incubation for 15 min, 500 
µl of 3, 5 Dintro salicylic acid reagents were added to both control 
and test. They were kept in a boiling water bath for 10 min. The 
absorbance was recorded at 540 nm using a UV–VIS 
spectrophotometer and the percentage of inhibition of alpha-
amylase enzyme was calculated using the formula. 
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Where ΔA is the absorbance of the control reaction, ΔA sample is 
absorbance of the test sample reaction.  
ΔA control = Absorbance Test–Absorbance Blank ΔA sample 
Absorbance Test–Absorbance Blank 
Positive controls and suitable reagent blank were simultaneously 
carried out and subtracted. The Inhibition percentage (%) was 
plotted against sample concentration (2, 4, 6, 8, 10 mg/ml) and a 
logarithmic regression curve was obtained to calculate the IC50. 
In vitro Alpha-glucosidase inhibition assay of T. chebula extract 
α-glucosidase inhibitory activities of all collected plant extract were 
conducted according to standard protocol [11]. 100 µl of plant 
extract was allowed to react with 100 µl of 20 mmol pNPG (p-
Nitrophenyl α-D glucopyranoside, Himedia RM 10294). To that 
mixture, 2.2 ml of 100 mmol phosphate buffer at pH 7.0 was added 
and then incubated for 10 min at 37 °C. The reaction was initiated by 
addition of 100 µl of alpha-glucosidase from Saccharomyces 
cerevisiae (Sigma, G5003) solution (1 mg/0.1 ml). It was followed by 
15 min incubation at 37 °C. 2.5 ml of 200 mmol Na2CO3 was added 
later, to stop the reaction. The absorbance of p Nitrophenol released 
from PNPG was measured in Spectrophotometer at 400 nm. The 
inhibition percentage of α-glucosidase activity was calculated by the 
following equation:  
 
Where, ΔA is the absorbance of the control reaction, ΔA sample is 
absorbance of the test sample reaction. 
ΔA control = Absorbance Test–Absorbance Blank ΔA sample = 
Absorbance Test–Absorbance Blank 
A dose-dependent alpha-amylase and alpha-glucosidase inhibitory 
activities were measured using an increasing concentration of plant 
sample (2, 4, 6, 8, 10 mg/ml) and the IC50 was calculated, IC50
For oral glucose tolerance test experimental animals were divided 
into two groups, normal and diabetic comprising of three subgroups 
consisting of six rats (n=6) in each group; In the Normal 
experimental group, three subgroups were there. Group I, Normal 
control rats received normal saline (5 ml vehicle); Group II, Normal 
rats treated with Plant extract in normal saline (300 mg/kg body 
weight); Group III, Normal rat treated with acarbose in normal 
saline (10 mg/kg body weight). Diabetic experimental groups: three 
subgroups were there. Group I, Diabetic control rats receiving 
normal saline (vehicle); Group II, Diabetic rat treated with plant 
extract in normal saline (300 mg/kg body weight). Group III, 
Diabetic rat, treated with acarbose in normal saline (10 mg/kg body 
weight). Thirty min after administration of vehicle (Normal saline), 
plant extract and acarbose respectively, all rats were given orally, 
glucose (2 g/kg body weight). The Postprandial blood glucose levels 
were measured before (0 min) and at 30, 60 and 120 min using a 
glucometer. Postprandial blood glucose curves of experimental rats 
were plotted and compared with those of control rats. 
Oral maltose tolerance test 
Six days after performing the glucose tolerance test, maltose 
tolerance test was performed in the same group of rats. The 
procedure for performing the maltose tolerance test was similar 
with glucose tolerance except that instead of glucose, maltose 
(3g/kg body weight) was orally administrated to all groups of rats, 
30 min after administration of the plant extract. 
Oral starch tolerance test 
Six days after performing the maltose tolerance test, starch 
tolerance test was performed in the same group of rats. Starch 
(3g/kg body weight) was orally administrated to all groups of rats, 
30 min after administration of the plant extract. 
Bioassay-guided fractionation and partial characterization of 
crude methanol extract of T. chebula leave 
The crude methanol extract of T. chebula leaves was subjected to 
column chromatography using silica gel 60–120 mesh for the 
isolation of bioactive antidiabetic principles. The column (300 x 18 
mm diameter) was packed with slurry of silica and petroleum ether 
and kept for overnight. Next morning plant sample (crude methanol 
extract of T. chebula leaves in powder form) was loaded over the 
packed column with the help of a spatula. The column was eluted 
with a solvent of increasing polarity. All fractions were analyzed in 
Merck TLC plates (20 cm x 20 cm) using a different proportion of 
hexane and ethyl acetate as mobile phase. Obtained fractions were 
tested for their in vitro hypoglycemic property using alpha-amylase 
and alpha-glucosidase enzymes using the same protocol mentioned 
earlier. The fraction showing highest in vitro hypoglycemic activity 
was finally accessed for its maltose tolerance in vivo in an alloxan-
induced diabetic rat model using the pre mention protocol. The 
isolated active fractions or band was further characterized using 
FTIR analysis for the identification of the active principle group 
involved in retarding the postprandial hyperglycemia. 
 
denotes that concentration of plant extract that is required to inhibit 
50% of enzyme activity. 
Induction of diabetes to experimental animal model 
Wistar rats (150-220 g) of either sex were used in this study. The 
rats were purchased from Assam veterinary college, Guwahati and 
Department of Zoology, Gauhati University. The animals were 
maintained under standard laboratory conditions at 25±2 °C and a 
normal photoperiod of 12h light and 12h dark cycle. The animals 
were made free access to water and standard diet. The experimental 
protocol was approved by Institutional ethical committee (Number–
IACE/PER/2015/01) of Gauhati University. Rats overnight fasted 
were given a single intraperitoneal injection of 155 mg/kg body wt. 
alloxan monohydrate (Sigma, USA) dissolved in freshly prepared 
normal saline (0.9%). Animals with fasting blood glucose over 200 
mg/dl, five days after alloxan administration were considered 
diabetic and were further taken for experimental studies. 
Oral carbohydrate tolerance test of MeOH extract of T. chebula 
leaves  
Oral glucose tolerance test 
Statistical analysis 
The results obtained were expressed in mean±SEM. The studied 
groups were compared using ANOVA test and Post Hoc Turkey HSD 
analysis was done to compare the mean. Values were considered to 
be significant when the p-value was less than 0.05. 
RESULTS AND DISCUSSION 
When accessed for α-amylase inhibitory activity at the concentration 
of 10 mg/ml, a mild inhibition of 70.46% was demonstrated by the 
extract compared to standard drug acarbose 80.21%. Whereas in 
case of enzyme alpha-glucosidase the same leave extract 
demonstrated a remarkable 100% inhibition compared to standard 
drug acarbose with 85.34% with a very minimum IC50 value of 
0.956±0.342 mg/ml (table 1).
 
Table 1: Alpha amylase and alpha glucosidase inhibitions–IC50 value calculation of Terminalia chebula leaves and standard drug 
acarbose, values are expressed as mean±SEM (n=3) 
Studied 
plant 
Alpha amylase IC50 
Value (mg/ml) 
Acarbose (mg/ml) Alpha glucosidase 
IC50 value (mg/ml) 
Acarbose (mg/ml) 
Terminalia 06.09±0.342 05.09±0.028 0.956±0.342 01.50±0.072 
chebula     
leaves     
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Oral carbohydrate tolerance test 
The effect of the crude extract of T. chebula leaves, and acarbose on 
oral carbohydrate tolerance test was performed in both normal and 
alloxan-induced diabetic rats using monosaccharide (glucose), 
disaccharide (maltose) and polysaccharide (starch). 
Oral glucose tolerance test 
A total of 36 rats were used for the carbohydrate tolerance test. 
The postprandial glucose variation was measured by loading 
both the experimental groups with glucose (2 gm/kg body 
weight). In glucose tolerance test, we found that the oral 
administration of acarbose (10 mg/body weight), 30 min before 
oral administration of glucose to 16 h fasted normal and diabetic 
rats were capable of suppressing the postprandial blood glucose 
level at 60 and 120 min compared to methanol extract of T. 
chebula leaves (fig. 1 and 2). 
 
 
Fig. 1: Oral glucose tolerance test in diabetic control (DC), 
values expressed as the mean±SEM (n=6) 
 
 
Fig. 2: Oral glucose tolerance test in normal control (NC). Values 
expressed as the mean±SEM (n=6) 
 
Oral maltose tolerance test 
A week after performing the oral glucose tolerance test, all the three 
groups were loaded with maltose (3 gm/kg body weight). In maltose 
tolerance test, oral administration of methanol extract of T. chebula 
leaves (300 mg/kg b. w) to diabetic rats significantly (*P<0.05) 
suppressed the rise of postprandial blood glucose level compared to 
the standard drug acarbose (fig. 3 and 4). 
 
Fig. 3: Oral maltose tolerance test in Diabetic control (DC), 
values expressed as the mean±SEM (n=6). *P<0.05 compared 
with standard drug acarbose 
 
 
Fig. 4: Oral maltose tolerance test in normal control (NC), values 
expressed as the mean±SEM (n=6) 
 
Oral starch tolerance test 
A week after performing the maltose tolerance test, all the three 
groups were loaded with starch (3 gm/kg body weight). In starch 
tolerance test, oral administration of standard drug acarbose (10 
mg/kg body weight), 30 min before oral administration of glucose to 
normal and diabetic rats was showed higher capability of 
suppressing the postprandial blood glucose level at 60 and 120 min 
compared to methanol extract of T. chebula leaves (fig. 5 and 6). 
 
 
Fig. 5: Oral starch tolerance test in diabetic control (DC), values 
expressed as the mean±SEM (n=6) 
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Fig. 6: Oral starch tolerance test in normal control (NC), values 
expressed as the mean±SEM (n=6) 
 
Bioassay-guided fractionation of crude methanol extract of T. 
chebula leaves 
The crude methanol extract being the most efficacious extract was later 
subjected to column chromatography for isolation of the active fraction 
using a different solvent system of increasing polarity. The column 
chromatography of crude methanol extract of T. chebula leaves using 
different solvent systems yielded 18 fractions. The collected fractions 
were later combined into six main fractions based on the Rf (Retention 
factor) value obtained by analytical thin layer chromatography. The in 
vitro enzyme inhibition study revealed that Fraction 5 (f5) demonstrated 
moderate alpha-amylase inhibition (IC50–42.86±0.56 µg/ml) compared 
to acarbose (IC50–45.06±1.01 µg/ml). However, the active fraction (f5) 
showed highest (P<0.01) alpha-glucosidase inhibition with a very 
minimum IC50 value of 39.58±0.98 µg/ml compared to acarbose (IC50–
55.56±1.07 µg/ml) (fig. 7 and 8). 
 
 
Fig. 7: Alpha amylase inhibition of selected six fractions, values 
are expressed as mean±SEM (n=3) 
 
Due to its mild alpha-amylase and high alpha-glucosidase 
inhibition activity, the fraction (f5) further selected for in vivo 
study in alloxan-induced diabetic rat model. In vivo maltose 
tolerance test of (f5) revealed that the leaves of T. chebula was 
capable of retarding the postprandial hyperglycemia significantly 
(*P<0.05, **P<0.01) from 245 mg/dL (reading taken at 30 min) to 
172 mg/dL (reading taken120 min) interval of time (fig. 9) 
compared to acarbose (230 mg/dL to 197 mg/dL) during the 
studied time interval (fig. 10). 
 
Fig. 8: Alpha-glucosidase inhibition of selected six fractions, 
values are expressed as mean±SEM (n=3), **
 
P<0.01 when 
compared with standard drug acarbose 
 
Fig. 9: Maltose tolerance test of F5 in diabetic rats, *P<0.05, 
**
 
P<0.01 when compared to normal control. A = Acarbose, f5 = 
Fraction 5, NC = Normal control, NS = Not significant, values are 
expressed as mean±SEM (n=6) 
 
Fig. 10: Maltose tolerance test of F5 in normal rats. * P<0.05, 
**P<0.01 when compared to diabetic control. A = Acarbose, f5 = 
Fraction 5, NC= Not significant, values are expressed as 
mean±SEM (n=6) 
 
The fraction (f5) demonstrated better result than acarbose in a 
diabetic group, however, when accessed in normal rat loaded with 
maltose, it was not found to be significant when compared 
statistically. The IR spectrum of the fraction exhibited broadband in 
the range, 3000–3500 cm-1 which are generally attributed to the-OH 
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stretching while the band observed at 1652 cm-1 corresponds to C=O 
stretching (fig. 11). The bands observed in the range, 2833.99-
2947.68 contributes to alkane C-H bond, 1540.54-1652.69–1500 
cm-1 are the due presence of N-H bonding, 1418.14-1506.68 are 
due to alkane C-H bond, while the ones at 1113.97 are due to ester 
linkage and that of 1000 cm-1 to 500 cm-1
 
 are assigned to aromatic 
C-H bending vibration. The FTIR analysis demonstrated the 
presence of several functional groups in the most active fraction 
(f5). Thin layer chromatographic separation of (f5) yielded 
another subfraction (f5a). The subfraction on HPLC analysis 
revealed the presence of the gallic acid as a major constituent (fig. 
12 and 13).
 
Fig. 11: FTIR spectra obtained for the active fraction (f5) 
 
 
Fig. 12: HPLC spectra of gallic acid standard 
 
 
Fig. 13: HPLC spectra of gallic acid isolated from T. chebula Retz leaves 
 
Diabetes mellitus is one of the fast-growing health problems in both 
developing and developed nations.  
Postprandial hyperglycemia that occurs due to impaired glucose 
tolerance (IGT) is alone a factor to double the risk of cardiovascular 
disease (CVD) [12-15]. There are many previous reports on the 
potentiality of the fruit part of T. chebula to inhibit enzyme alpha-
glucosidase [16-18]. Several earlier studies conducted on the fruit 
part of T. chebula demonstrated potent maltase inhibitory activity 
due to the presence of three active ellagitannin (chebulanin, 
chebulagic acid and chebulinic acid [19]. Plant-derived hydrolyzable 
tannin is known to be responsible for varied pharmacological 
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activity including antidiabetic [20–24]. Gallic acid being one of the 
widely spread hydrolyzable tannins of T. chebula possess very high 
antioxidant and hypoglycemic property [25, 26]. Recent studies 
indicate that plant-derived ploy phenols, because of its antioxidant 
and anti-inflammatory properties, attribute maximum towards the 
hypoglycemic effect via several modes like reduction of the 
intestinal absorption of dietary carbohydrate, improvement of β-cell 
function, improvement of insulin action, modulation of the some 
enzymes involved in glucose metabolism [27–30]. The enzyme α 
glucosidase inhibitors fall under one of the categories of oral 
hypoglycemic agents that are generally used for the treatment of 
diabetes. α-glucosidase inhibitory compounds are abundant in 
nature, and those with very promising inhibitory potentiality can be 
clinically employed for treating diabetes mellitus type 2. 
CONCLUSION 
The present study concludes that a leaf of T. chebula is a potential 
inhibitor of enzyme alpha-glucosidase that plays a crucial role in 
intensifying the postprandial hyperglycemic condition. In future, 
more vigorous and authentic screening of ethnic knowledge-based 
antidiabetic plants is needed to be done, for the development of 
some effective bio formulations. Such formulations in the coming 
future will definitely combat metabolic syndrome like diabetes and 
complications associated with the disease. 
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